Lifeline Scientific, Inc
10 March 2008
Monday 10 March 2008
Lifeline Scientific, Inc
('Lifeline' or 'the Company')
Lifeline division wins contracts to supply two leading transplant centres
with the LifePort(R) Kidney Transporter
Lifeline Scientific, the medical technology company, announces that its Organ
Recovery Systems division has signed contracts for its LifePort(R) Kidney
Transporter with two of the world's largest kidney transplant centres, the
Alabama Organ Center and the University Hospital of Wisconsin. Each has elected
to use LifePort (R) to transport and preserve deceased donor kidneys offered
for transplantation in their centres, which are reported to number, on average,
These contracts involve the sale of 14 LifePort Kidney Transporters as well as a
significant volume of consumables each year. The contracts also cover ongoing
warranty and maintenance services.
David Kravitz, Chief Executive of Lifeline Scientific, said:
'Securing contracts from two of the world's leading transplant centres is a
significant accomplishment for our Organ Recovery Systems division, especially
as it comes so soon after the completion of our IPO in January. Furthermore,
adoption of our LifePort Kidney Transporter as standard practice in such
prominent kidney transplant centres is a strong vote of confidence for our
product. While January and February trading results have met management
expectations, these contracts support our well paced momentum to meet our
targets for 2008.
'With a continuing global shortage of organs for transplantation, it is
important to find ways of increasing not only the number of kidneys available
but also the quality of those organs which improves post transplant outcomes for
Lifeline Scientific, Inc.
David Kravitz, CEO
Seymour Pierce (Nomad) +44 (0)20 7107 8000
Mark Percy / Huaizheng Peng / Sarah Jacobs
Financial Dynamics +44 (0)20 7831 3113
Ben Brewerton / John Dineen
Notes to Editors
The LifePort Kidney Transporter preservation system is the Group's lead product.
It is designed with the challenges of organ recovery and transport in mind,
and provides a sealed, sterile, protected environment where a chemical solution
is gently pumped through the donated kidney at cold temperatures to minimise
tissue damage while the organ is outside the body.
Since receiving FDA clearance and CE Marking in 2004, over 250 LifePorts have
been introduced in leading transplant programs throughout Europe and North
America, preserving more than 10,000 kidneys for clinical transplantation.
Retrospective clinical outcomes studies have shown that machine preservation
improves the quality of a kidney from a cadaveric donor prior to transplantation
in comparison to organs statically stored in a traditional cool box. This data
demonstrates that machine perfused kidneys are more likely to function
immediately after transplantation and to remain healthier for longer.
This information is provided by RNS
The company news service from the London Stock Exchange